MINA THERAPEUTICS
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. Its technology helps transform the therapy landscape of cancer and other severe diseases that enable doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells. The company was founded in 2008 and is headquartered in London, England.
MINA THERAPEUTICS
Industry:
Biotechnology Genetics Life Science Pharmaceutical
Founded:
2008-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.minatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
89.51 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Google Maps Contact Form 7 WordPress 6.0 WPBakery
Current Advisors List
Current Employees Featured
Founder
Investors List
Eli Lilly
Eli Lilly investment in Corporate Round - MiNA Therapeutics
aMoon Fund
aMoon Fund investment in Series A - MiNA Therapeutics
Sosei Group
Sosei Group investment in Corporate Round - MiNA Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-12 | MiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of Growth |
Official Site Inspections
http://www.minatx.com Semrush global rank: 9.91 M Semrush visits lastest month: 85
- Host name: s58.cyber-folks.pl
- IP address: 185.208.164.58
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "MiNA Therapeutics"
MiNA Therapeutics | RNA Activation – MiNA Therapeutics | RNA …
MiNA Therapeutics is the global leader in small activating RNA therapeutics or RNAa. Harnessing innate mechanisms of gene activation, RNAa therapeutics are a revolutionary new class of …See details»
MiNA Therapeutics - Crunchbase Company Profile
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. View contacts for MiNA Therapeutics to access new leads and connect with decision-makers.See details»
MiNA Therapeutics Enters Research Collaboration with Nippon …
London, United Kingdom, 4 April 2024 -- MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a research collaboration and licensing agreement …See details»
MiNA Therapeutics - LinkedIn
Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our...See details»
MiNA Therapeutics Limited - VentureRadar
Website: http://www.minatx.com/ Pioneers small activating RNA therapeutics to upregulate gene expression, offering novel treatments for diseases through endogenous gene activation …See details»
MiNA Therapeutics Enters Research Collaboration with BioMarin ...
Apr 25, 2023 · Under the agreement, BioMarin will employ MiNA Therapeutics’ proprietary RNAa algorithm and technology platform to identify and characterize RNAa molecules targeting a …See details»
Contacts, Employees, Board Members, Advisors & Alumni
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.See details»
MiNA Therapeutics Appoints Peter Bains as Chief Business Officer
Sep 29, 2020 · LONDON-- ( BUSINESS WIRE )--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business …See details»
ABOUT – MiNA Therapeutics | RNA Activation
MiNA Therapeutics is the global leader in small activating RNA therapeutics or RNAa. Harnessing innate mechanisms of gene activation, RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal …See details»
MiNA Therapeutics Appoints Two Independent …
Dec 21, 2021 · MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines...See details»
MiNA Completes Exclusive License Agreement with University of ...
Nov 18, 2014 · MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of …See details»
MiNA Therapeutics Appoints Peter Bains as Chief Business Officer
Sep 29, 2020 · LONDON-- ( BUSINESS WIRE )-- MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business …See details»
MiNA Therapeutics - Funding, Financials, Valuation & Investors
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.See details»
MiNA Therapeutics Enters Research Collaboration with Nippon
Apr 4, 2024 · MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; …See details»
MiNA Therapeutics expands senior leadership team with four new …
A revolutionary new class of medicines that can restore or boost normal function in patients' cells. We are advancing a proprietary pipeline of new medicines with an initial focus on cancer and …See details»
MiNA Therapeutics Announces Research Collaboration with …
Jan 7, 2020 · LONDON-- ( BUSINESS WIRE )--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to …See details»
Lilly and MiNA Therapeutics Announce saRNA Research …
May 11, 2021 · Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly 's key therapeutic …See details»
PIPELINE – MiNA Therapeutics | RNA Activation - minatx.com
Through transcriptional activation, RNAa therapeutics promise a revolution in our ability to modulate previously undruggable targets. Sickle Cell Disease (SCD) and Beta Thalassemia …See details»
MiNA Therapeutics Presents Proof of Mechanism Data on MTL …
Apr 11, 2022 · LONDON-- ( BUSINESS WIRE )--MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (RNAa) therapeutics, presents preclinical …See details»
MiNA Therapeutics Expands Senior Leadership Team With Four …
Starting 25 October 2021, Troels will lead MiNA’s chemistry research and strategy. Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building.See details»